You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentazocine
Accession NumberDB00652  (APRD01173)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Structure
Thumb
Synonyms
Fortral
Pentazocin
Pentazocina
Pentazocine
Pentazocinum
External Identifiers
  • CS 350
  • NIH 7958
  • Win 20228
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TalwinInjection, solution30 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2010-10-12Not applicableUs
TalwinInjection, solution30 mg/mLIntramuscular; Intravenous; SubcutaneousHospira, Inc.2010-10-12Not applicableUs
TalwinInjection, solution30 mg/mLIntramuscular; Intravenous; SubcutaneousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
TalwinTablet50 mgOralSanofi Aventis Canada Inc1970-12-31Not applicableCanada
Talwin - Liq 30mg/mlLiquid30 mgIntramuscular; Intravenous; SubcutaneousSanofi Synthelabo Canada Inc1967-12-312001-08-10Canada
Talwin 30 mg/mlSolution30 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation2002-11-01Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FortalSanofi-Aventis
FortralSanofi-Aventis
FortwinTerapia
PangonL.B.S.
PentaginDaiichi Sankyo
SosegonSanofi-Aventis
StopainBeximco
Talwin PXSanofi-Aventis
Brand mixtures
NameLabellerIngredients
Pentazocine and NaloxoneLake Erie Medical & Surgical Supply DBA Quality Care Products LLC
Pentazocine HCl and AcetaminophenRebel Distributors Corp
Pentazocine HCl and Naloxone HClSTAT Rx USA LLC
Pentazocine Hydrochloride and AcetaminophenGAVIS Pharmaceuticals, LLC
Pentazocine Hydrochloride and Naloxone HydrochlorideGAVIS Pharmaceuticals, LLC
Salts
Name/CASStructureProperties
Pentazocine Hydrochloride
ThumbNot applicableDBSALT001009
Pentazocine Lactate
ThumbNot applicableDBSALT001010
Categories
UNIIRP4A60D26L
CAS number359-83-1
WeightAverage: 285.4238
Monoisotopic: 285.209264491
Chemical FormulaC19H27NO
InChI KeyVOKSWYLNZZRQPF-GDIGMMSISA-N
InChI
InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
IUPAC Name
(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0²,⁷]trideca-2,4,6-trien-4-ol
SMILES
C[[email protected]]1[[email protected]]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C
Pharmacology
IndicationFor the relief of moderate to severe pain.
Structured Indications
PharmacodynamicsPentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.
Mechanism of actionThe preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
antagonist
HumanP35372 details
Kappa-type opioid receptorProteinyes
agonist
HumanP41145 details
Sigma non-opioid intracellular receptor 1Proteinyes
agonist
HumanQ99720 details
Related Articles
AbsorptionWell absorbed from the gastro-intestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationNot Available
Half life2 to 3 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pentazocine Action PathwayDrug actionSMP00686
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alfaxalone.Vet Approved
AlfentanilPentazocine may decrease the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
AlphacetylmethadolPentazocine may decrease the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Pentazocine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pentazocine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Asenapine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pentazocine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azaperone.Vet Approved
AzelastinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pentazocine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzyl alcohol.Approved
BezitramidePentazocine may decrease the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Pentazocine.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentazocine.Approved, Investigational
BuprenorphinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Pentazocine.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine.Approved
CarfentanilPentazocine may decrease the analgesic activities of Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pentazocine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Pentazocine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pentazocine.Approved, Vet Approved
CitalopramPentazocine may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine.Approved
CocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cocaine.Approved, Illicit
CodeinePentazocine may decrease the analgesic activities of Codeine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentazocine.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentazocine.Approved
DapoxetinePentazocine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.Approved
DesvenlafaxinePentazocine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pentazocine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pentazocine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
DextromoramidePentazocine may decrease the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePentazocine may decrease the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocinePentazocine may decrease the analgesic activities of Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Pentazocine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Difenoxin.Approved, Illicit
DihydrocodeinePentazocine may decrease the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphinePentazocine may decrease the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePentazocine may decrease the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine.Approved
DiphenoxylatePentazocine may decrease the analgesic activities of Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
DPDPEPentazocine may decrease the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drotebanol.Experimental, Illicit
DuloxetinePentazocine may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pentazocine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pentazocine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine.Approved
EluxadolinePentazocine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pentazocine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone.Approved
EscitalopramPentazocine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.Approved
EthanolPentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentazocine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pentazocine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphinePentazocine may decrease the analgesic activities of Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentazocine.Approved
EtoperidonePentazocine may increase the serotonergic activities of Etoperidone.Approved
EtorphinePentazocine may decrease the analgesic activities of Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylPentazocine may decrease the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunitrazepam.Approved, Illicit
FluoxetinePentazocine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pentazocine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pentazocine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pentazocine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pentazocine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pentazocine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.Approved, Vet Approved
HeroinPentazocine may decrease the analgesic activities of Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pentazocine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide.Approved
HydromorphonePentazocine may decrease the analgesic activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Pentazocine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.Approved
IndalpinePentazocine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isoflurane.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam.Approved
KetobemidonePentazocine may decrease the analgesic activities of Ketobemidone.Approved
KW-3902The risk or severity of adverse effects can be increased when Pentazocine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levodopa.Approved
Levomethadyl AcetatePentazocine may decrease the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranPentazocine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolPentazocine may decrease the analgesic activities of Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pentazocine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Pentazocine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.Approved
LofentanilPentazocine may decrease the analgesic activities of Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentazocine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Pentazocine is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Pentazocine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Pentazocine.Investigational
MephentermineMephentermine may increase the analgesic activities of Pentazocine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.Approved
MethadonePentazocine may decrease the analgesic activities of Methadone.Approved
Methadyl AcetatePentazocine may decrease the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Pentazocine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine.Approved
MethotrimeprazinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Pentazocine.Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Pentazocine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.Approved
MetyrosinePentazocine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.Approved, Illicit
MilnacipranPentazocine may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Investigational
MirtazapinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Pentazocine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Pentazocine.Approved, Withdrawn
MorphinePentazocine may decrease the analgesic activities of Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Pentazocine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Investigational
NalbuphinePentazocine may decrease the analgesic activities of Nalbuphine.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Naloxegol.Approved
NaltrexoneThe therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodonePentazocine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrous oxide.Approved, Vet Approved
NormethadonePentazocine may decrease the analgesic activities of Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Pentazocine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron.Approved
OpiumPentazocine may decrease the analgesic activities of Opium.Approved, Illicit
OrphenadrinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.Approved, Investigational
OxycodonePentazocine may decrease the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphonePentazocine may decrease the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentazocine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.Approved
ParaldehydePentazocine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetinePentazocine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
PerazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine.Approved
PethidinePentazocine may decrease the analgesic activities of Pethidine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Pentazocine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.Experimental
PiritramidePentazocine may decrease the analgesic activities of Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.Approved, Vet Approved
PramipexolePentazocine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentazocine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pentazocine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pentazocine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Pentazocine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Pentazocine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Pentazocine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Pentazocine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon.Approved, Investigational
RamosetronPentazocine may increase the constipating activities of Ramosetron.Approved
RemifentanilPentazocine may decrease the analgesic activities of Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pentazocine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Pentazocine.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Romifidine.Vet Approved
RopinirolePentazocine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentazocine.Approved
RotigotinePentazocine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pentazocine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pentazocine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Pentazocine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pentazocine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sertindole.Approved, Withdrawn
SertralinePentazocine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Pentazocine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Pentazocine.Approved
SufentanilPentazocine may decrease the analgesic activities of Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pentazocine.Approved
SuvorexantPentazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrodotoxin.Investigational
ThalidomidePentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Pentazocine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pentazocine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiapride.Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pentazocine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.Approved
TramadolPentazocine may decrease the analgesic activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pentazocine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine.Approved
Uc1010The risk or severity of adverse effects can be increased when Pentazocine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Pentazocine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pentazocine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.Approved
VenlafaxinePentazocine may increase the serotonergic activities of Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide.Approved
ZimelidinePentazocine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zolazepam.Vet Approved
ZolpidemPentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02AD01
AHFS Codes
  • 28:08.12
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9931
Blood Brain Barrier+0.9769
Caco-2 permeable+0.7902
P-glycoprotein substrateSubstrate0.9014
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6975
Renal organic cation transporterInhibitor0.6982
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7819
CYP450 1A2 substrateInhibitor0.5886
CYP450 2C9 inhibitorNon-inhibitor0.8321
CYP450 2D6 inhibitorInhibitor0.8147
CYP450 2C19 inhibitorNon-inhibitor0.8585
CYP450 3A4 inhibitorNon-inhibitor0.8155
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.778
Ames testNon AMES toxic0.8231
CarcinogenicityNon-carcinogens0.9322
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity2.4411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6301
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
Injection, solutionIntramuscular; Intravenous; Subcutaneous30 mg/mL
TabletOral50 mg
LiquidIntramuscular; Intravenous; Subcutaneous30 mg
SolutionIntramuscular; Intravenous; Subcutaneous30 mg
Prices
Unit descriptionCostUnit
Talwin 30 mg/ml vial14.78USD ml
Talwin 30 mg/ml ampul4.86USD ml
Talwin 30 mg/ml1.64USD ml
Talwin 50 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point146.3 °CPhysProp
logP4.64DAYLIGHT (1999)
pKa8.88SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.122 mg/mLALOGPS
logP4.44ALOGPS
logP3.89ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)7.59ChemAxon
pKa (Strongest Basic)12.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity89.8 m3·mol-1ChemAxon
Polarizability33.86 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 6,7-benzomorphans. These are opioid alkaloids based on the tricyclic 6,7-benzomorphan skeleton. Benzomorphans lack the C ring of morphine.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
Class6,7-benzomorphans
Sub ClassNot Available
Direct Parent6,7-benzomorphans
Alternative Parents
Substituents
  • 6,7-benzomorphan
  • Benzazocine
  • Tetralin
  • Aralkylamine
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine. Pain. 1988 Jun;33(3):369-72. [PubMed:3419842 ]
  2. Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44. [PubMed:6094791 ]
  3. Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10. [PubMed:8042002 ]
  4. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  5. Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82. [PubMed:2286420 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitt...
Gene Name:
SIGMAR1
Uniprot ID:
Q99720
Molecular Weight:
25127.52 Da
References
  1. Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445 ]
  2. Colabufo NA, Contino M, Inglese C, Niso M, Perrone R, Roperto S, Roperto F: In vitro and ex vivo characterization of sigma-1 and sigma-2 receptors: agonists and antagonists in biological assays. Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):161-71. [PubMed:20021350 ]
  3. Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB: Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94. [PubMed:17898305 ]
  4. Mamolo MG, Zampieri D, Zanette C, Florio C, Collina S, Urbano M, Azzolina O, Vio L: Substituted benzylaminoalkylindoles with preference for the sigma2 binding site. Eur J Med Chem. 2008 Oct;43(10):2073-81. Epub 2007 Sep 26. [PubMed:18069094 ]
  5. Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, Ruoho AE: Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol. 2007 Oct;72(4):921-33. Epub 2007 Jul 10. [PubMed:17622576 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23